证券代码：300147 证券简称：ST 香雪 公告编号：2025-033 广州市香雪制药股份有限公司 关于申请借款续期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、借款续期概述 （一）根据业务发展需要，广州市香雪制药股份有限公司（以下简称"公司"） 向广州农村商业银行股份有限公司黄埔支行申请人民币 55,000 万元借款续期， 借款续期不超过一年，用于公司的经营生产发展。本次借款续期由公司子公司广 州香雪云埔产业投资有限公司、广州香岚健康产业有限公司、公司控股股东广州 市昆仑投资有限公司、实际控制人王永辉、陈淑梅及广东厚朴实业有限公司提供 最高额连带责任保证担保，由公司持有的广州香雪云埔产业投资有限公司、广州 香岚健康产业有限公司股权提供最高额质押担保，以及由公司及广州香岚健康产 业有限公司所持有的厂房、土地使用权、在建工程予以提供最高额抵押担保。本 次担保事项属于以公司全资子公司及公司自身的资产为公司提供担保，全资子公 司广州香岚健康产业有限公司、广州香雪云埔产业投资有限公司已履行了内部审 议程序同意继续为借款续期提供担保。 （二）履行的审批程 ...

1、股东会的届次：2024 年年度股东会 2、会议召集人：公司董事会 3、会议召开的合法、合规性：本次股东会召开经公司第九届董事会第二十八 次会议审议通过，召集程序符合有关法律、行政法规、部门规章、规范性文件和 《公司章程》的规定。 4、会议召开日期、时间： 现场会议召开日期和时间：2025 年 6 月 27 日（星期五）上午 10:00 证券代码：300147 证券简称：ST 香雪 公告编号：2025—032 广州市香雪制药股份有限公司 关于召开 2024 年年度股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》《广州市香雪制药股份有限公司章程》（以下 简称"《公司章程》"）的有关规定，经广州市香雪制药股份有限公司（以下简称 "公司"）第九届董事会第二十八次会议审议通过，决定于2025年6月27日召开 2024年年度股东会，现将会议有关事宜通知如下： 一、 本次股东会的基本情况 网络投票日期和时间：2025 年 6 月 27 日。其中，通过深圳证券交易所交易系 统进行网络投票的时间为 2025 年 6 月 27 日上午 ...

会议同意 2025 年 6 月 27 日（星期五）上午 10 时在公司本部召开 2024 年年 度股东会。 具体内容详见公司在巨潮资讯网披露的《关于召开 2024 年年度股东会的通 知》。 表决结果：同意 6 票、反对 0 票、弃权 0 票。 二、审议通过了《关于申请借款续期的议案》 证券代码：300147 证券简称：ST 香雪 公告编号：2025-031 广州市香雪制药股份有限公司 第九届董事会第二十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广州市香雪制药股份有限公司（以下简称"公司"）第九届董事会第二十八 次会议于 2025 年 6 月 6 日在公司本部会议室以现场结合通讯方式召开，会议通 知已于 2025 年 6 月 3 日以邮件、电话等方式送达了全体董事。会议应参加董事 六名，实际参加董事六名，独立董事吴杰先生、周庆权先生、陶剑虹女士以通讯 方式出席，无委托出席的情况，公司监事和高级管理人员等相关人员列席了本次 会议，会议由董事长王永辉先生主持。本次会议的召开、议事方式和表决程序符 合《中华人民共和国公司法》和《公司章程》对召开 ...

Core Viewpoint - Guangzhou Xiangxue Pharmaceutical Co., Ltd. (hereinafter referred to as "Xiangxue Pharmaceutical" or "ST Xiangxue") is facing significant legal challenges, ongoing financial losses, and regulatory scrutiny, raising questions about its future viability and potential for recovery [1][6][9]. Legal Issues - Xiangxue Pharmaceutical has been involved in over 140 lawsuits, including disputes related to projects, construction, operations, and loans [3][10]. - A recent court ruling mandates Xiangxue Pharmaceutical to repay a total of 121 million yuan (approximately 18 million USD) to Hubei Qingsong Yuetian Pharmaceutical Co., Ltd., including principal and interest payments [1][5]. Financial Performance - The company has experienced continuous financial losses, with net losses of 5.30 billion yuan (approximately 800 million USD) in 2022, 3.89 billion yuan (approximately 570 million USD) in 2023, and projected losses of 8.59 billion yuan (approximately 1.3 billion USD) in 2024 [5]. - In Q1 2024, Xiangxue Pharmaceutical reported a revenue of 421 million yuan (approximately 60 million USD), a year-on-year decline of 25.99%, with a net loss of 877.3 million yuan (approximately 130 million USD) [5]. Regulatory Scrutiny - The company and its actual controller, Wang Yonghui, are under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [7][8]. - Xiangxue Pharmaceutical has been penalized for failing to disclose significant losses related to the demolition of properties and for not reporting non-operating fund occupation by related parties, leading to fines totaling 20.65 million yuan (approximately 3 million USD) [9]. Strategic Direction - Despite its challenges, Xiangxue Pharmaceutical is attempting to pivot from traditional Chinese medicine to the biopharmaceutical sector, focusing on innovative drug development, particularly in oncology [9][10]. - The company has introduced several new drug projects, including TCR-T cell therapy, which has been recognized as a breakthrough treatment [9].

Core Viewpoint - ST Xiangxue is facing significant financial pressure due to a court ruling requiring repayment of over 1.21 billion yuan to Hubei Qingsong Yuyao Co., which is part of a larger issue involving numerous lawsuits and debts [2][3] Group 1: Financial Obligations - ST Xiangxue is required to repay two loans totaling 121.2 million yuan, with the first loan of 81.2 million yuan accruing interest at 14.6% and the second loan of 40 million yuan at 3.1% starting from December 2024 [3] - The company also faces additional costs including 600,000 yuan in legal fees and 800,000 yuan in case acceptance fees [3] - The company has pledged shares worth 60 million yuan as collateral for the first loan, giving the lender priority in repayment if obligations are not met [3] Group 2: Financial Performance - ST Xiangxue is projected to incur a net loss of 859 million yuan in 2024, primarily due to high financial expenses and previous legal costs totaling 92 million yuan [4] - The company reported a net cash flow from operating activities of -82.46 million yuan in the first quarter, a year-on-year decline of 419.44% [4] - As of the end of Q1 2025, the company's debt ratio reached 81.75%, with short-term loans of 1.374 billion yuan and long-term loans of 201 million yuan, while cash reserves were only 57.52 million yuan [4] Group 3: Legal and Operational Challenges - ST Xiangxue is entangled in over 143 lawsuits, with 103 related to operational issues, indicating severe legal challenges [5] - The company has been selling off subsidiaries to alleviate debt, but remains heavily indebted despite these efforts [5] - ST Xiangxue entered a pre-restructuring process due to a 66 million yuan debt claim, highlighting its inability to meet financial obligations [6] Group 4: Regulatory Issues - The company and its controlling shareholder are under investigation for information disclosure violations, with penalties including a fine of 6 million yuan and a 5-year market ban for the shareholder [7] - The investigation has led to a change in the company's stock designation to "ST Xiangxue," reflecting its financial distress [7] Group 5: Restructuring Efforts - ST Xiangxue has appointed a legal team to manage its pre-restructuring phase, aiming to facilitate communication with creditors and potential investors [8] - The approval of the pre-restructuring does not guarantee a successful restructuring process, and the company still faces the risk of bankruptcy if restructuring fails [8]

Core Viewpoint - ST Xiangxue is facing significant financial challenges, including a court ruling requiring repayment of loans totaling 1.2 billion yuan, amidst ongoing legal disputes and declining revenues [1][2][3] Group 1: Financial Obligations - ST Xiangxue is required to repay two loans to Hubei Qingsong Yuyao Co., with a total principal of 1.2 billion yuan and accumulated interest nearing 20 million yuan [1] - The first loan of 812 million yuan has an interest rate of 14.6%, while the second loan of 400 million yuan has an interest rate of 3.1% [1][2] - The company has pledged shares worth 600 million yuan as collateral for the loans, giving the lender priority in repayment if obligations are not met [2] Group 2: Legal Issues - The company is currently involved in 143 lawsuits and arbitration cases, with 103 related to operational matters [2][3] - A recent court decision has allowed the company to enter a pre-restructuring phase, which lasts for three months, but does not guarantee formal restructuring [3] Group 3: Financial Performance - In 2024, ST Xiangxue reported a revenue of 1.859 billion yuan, a decline of 19.16% year-on-year, and an increased net loss of 859 million yuan compared to a loss of 389 million yuan in 2023 [2][3] - The first quarter of 2025 showed a revenue of 421 million yuan, down 25.99% year-on-year, with a net loss of 877 million yuan, worsening from a loss of 356 million yuan in the same period last year [3] - The company’s cash flow from operating activities was negative 824 million yuan, a decline of 419.44% year-on-year [3]

Core Viewpoint - Guangzhou Xiangxue Pharmaceutical Co., Ltd. is involved in a legal dispute with Hubei Qingsong Yuyue Pharmaceutical Co., Ltd. regarding loan repayment, with a court ruling mandating repayment of principal and interest, which the company is actively addressing to protect its interests [1][2]. Group 1: Legal Judgment Details - The court ordered Hubei Qingsong Yuyue Pharmaceutical Co., Ltd. to repay a principal amount of 81.2 million yuan and interest calculated at a rate of 14.6% until the actual repayment date [1]. - Additionally, the company is required to pay 4 million yuan in principal and associated interest, along with 600,000 yuan in legal fees [1]. - The ruling grants the plaintiff, Hubei Qingsong Yuyue Pharmaceutical Co., Ltd., a priority right to the proceeds from the pledged shares of Hubei Tianji Pharmaceutical Co., Ltd. valued at 60 million yuan [1]. Group 2: Impact on the Company - The company is in active communication with Hubei Qingsong Yuyue Pharmaceutical Co., Ltd. to seek a resolution to the dispute, aiming to safeguard the interests of the company and its shareholders [2]. - The ongoing litigation is not expected to have a significant impact on the company's production operations or financial status [2]. - The company has pledged its shares in Hubei Tianji Pharmaceutical Co., Ltd. as part of the legal proceedings [2].

证券代码:300147 证券简称: ST 香雪 公告编号:2025—030 广州市香雪制药股份有限公司 关于涉及重大诉讼案进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广州市香雪制药股份有限公司（以下简称"公司"）与湖北青松逾越医药有 限公司因借贷纠纷的诉讼事项，已于 2024 年 12 月 14 日在巨潮网披露了《关于 累计诉讼事项的公告》（公告编号:2024—060）。近日公司收到了湖北省武汉市江 汉区人民法院出具的《民事判决书》（2024）鄂 0103 民初 15837 号，情况如下： 一、判决情况 1、被告广州市香雪制药股份有限公司于本判决生效之日起十日内向原告湖 北青松逾越医药有限公司偿还借款本金 8,120 万元，并支付借款利息（截至 20 23 年 12 月 28 日利息 13,124,240 元，此后利息以 8,120 万元为基数，按照年 利率 14.6%的标准计算至实际清偿之日止）； 2、被告广州市香雪制药股份有限公司于本判决生效之日起十日内向原告湖 北青松逾越医药有限公司偿还借款本金 4,000 万元，并支付借款利息（以 4, ...

Group 1 - The cell immunotherapy concept index rose by 1.25%, ranking 6th among concept sectors, with 29 stocks increasing in value [1][2] - Notable gainers included Ruizhi Pharmaceutical with a 20% limit up, Hainan Haiyao at limit up, and Shutaishen, Guanhao Biological, and Fosun Pharma with increases of 15.02%, 8.88%, and 5.23% respectively [1][6] - The sector experienced a net outflow of 266 million yuan, with 20 stocks seeing net inflows, and 8 stocks receiving over 10 million yuan in net inflows, led by Hainan Haiyao with a net inflow of 144 million yuan [2][3] Group 2 - Hainan Haiyao, Anke Bio, and Dongcheng Pharmaceutical had the highest net inflow ratios at 35.56%, 5.52%, and 5.27% respectively [3][4] - The top stocks by net inflow included Hainan Haiyao, Fosun Pharma, Ruizhi Pharmaceutical, and Zhaoyan New Drug, with net inflows of 144 million yuan, 54.52 million yuan, 34.78 million yuan, and 31.86 million yuan respectively [2][3] - Stocks with significant declines included Xue Rong Biological, Saifutian, and Jinchang Protein, with decreases of 4.23%, 2.74%, and 2.61% respectively [1][5]

Core Viewpoint - The implementation of the Private Economy Promotion Law is a significant step in supporting the development of the private economy in Guangzhou, providing a solid foundation for achieving the goal of "Greatly Developing Guangzhou in Twelve Years" [1][2]. Group 1: Legislative Framework - The Private Economy Promotion Law is China's first foundational law specifically aimed at the development of the private economy, consisting of 9 chapters and 78 articles, establishing a comprehensive system for promoting fair competition, investment financing, technological innovation, and legal protections [2]. - This law transforms effective practices from the Party's policies since the 18th National Congress into a legal framework, ensuring equal access to production factors and market participation for private enterprises [2][3]. Group 2: Local Implementation in Guangzhou - Guangzhou has been a pioneer in the rise of the private economy since the reform and opening up, with significant contributions to the city's economic and social development [3]. - The city has introduced various measures and regulations to support the private economy, including the "Measures for Promoting the Development of the Private Economy in Guangzhou" and the "Regulations on Supporting the Development of the Private Economy in Guangzhou" [4]. Group 3: Economic Impact and Goals - By 2024, the added value of the private economy in Guangzhou is expected to account for 42.3% of GDP, an increase of 0.8 percentage points from 2023, contributing 52.5% to the city's economic growth [4]. - The law aims to enhance the development environment for private enterprises, improve service levels, and address challenges faced by private businesses [5][6]. Group 4: Focus on Innovation and Support - The law emphasizes the importance of technological innovation and aims to alleviate financing difficulties for private enterprises, encouraging them to participate in major projects and initiatives [8][10]. - It establishes a framework for fair competition and supports private enterprises in expanding their market reach and enhancing their competitiveness [9][13]. Group 5: Key Stakeholder Perspectives - Various stakeholders, including business leaders and government officials, express confidence that the Private Economy Promotion Law will boost private enterprise development, enhance innovation, and create a more favorable business environment [10][11][12]. - The law is seen as a critical tool for protecting the rights of private enterprises and fostering a culture of innovation and competitiveness within the private sector [12][14].